Review: Mitochondrial Complexes as Proposed Targets in Aging
This review links structural and functional changes in mitochondrial complexes to cellular senescence and age-related disease, and proposes therapies such as ETC stabilizers, mPTP inhibitors and CRISPR correction as a framework, not validated treatments. [1]
Automatic summary · not editorially reviewed
The key findings
The review states that mitochondrial complexes, including the electron transport chain, mPTP and protein quality control systems, play pivotal roles in aging and age-related diseases. [1]
Proposed strategies include small-molecule ETC supercomplex stabilizers, peptide-based mPTP inhibitors and CRISPR-mediated correction of mtDNA-protein mismatches. [1]
The review categorizes nine age-associated diseases by their dependence on distinct mitochondrial complexes and offers a framework, not validated treatments. [1]
The source at a glance
- Study type / format
- Review article (abstract)
- Population / context
- Mitochondria and their biomacromolecular complexes in aging and nine age-associated diseases
- Summary based on
- Study abstract
- Original publication
- October 1, 2026
Review links mitochondrial complex changes to senescence
The review states that mitochondria and their biomacromolecular complexes, including the electron transport chain, the mitochondrial permeability transition pore and protein quality control systems, play pivotal roles in aging and age-related diseases. It integrates recent insights into how structural and functional disruptions of these complexes drive cellular senescence and systemic decline. It describes the architecture of mitochondrial assemblies needed for energy production and organelle stability, such as oxidative phosphorylation complexes and interactions between mitochondrial DNA and proteins.
Supporting source [1]
Proposed strategies and tissue-specific examples
According to the review, age-related changes in stoichiometry, conformational states such as mPTP opening, and post-translational modifications such as SIRT3-mediated acetylation compromise mitochondrial integrity, fueling metabolic dysfunction and chronic inflammation, called inflammaging. Proposed therapeutic strategies include small-molecule stabilizers of ETC supercomplexes, peptide-based mPTP inhibitors and CRISPR-mediated correction of mtDNA-protein mismatches. Tissue-specific models are cited as examples of clinical relevance: Complex I in skin aging and Bcl-2 protein imbalance in ovarian aging.
Supporting source [1]
Nine diseases categorized by mitochondrial complex dependence
The review categorizes nine age-associated diseases, covering neurodegenerative, cardiovascular and cancer types, based on their dependence on distinct mitochondrial complexes. Examples given are ATP synthase in cancer resistance and the TIM/TOM import machinery in Alzheimer's disease. The authors say that linking structural findings, such as cryo-EM studies, with therapeutic innovation offers a framework for targeting mitochondrial complexes to mitigate aging and its related pathologies. This is a proposed framework; the abstract reports no clinical trial results or validated treatments.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No clinical trial results, effect sizes or validated treatments are reported in the abstract. The therapeutic strategies and the framework are proposals.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhang X, Tao T, Liu W, Xie A, Liang Y, Zhu X. · europepmc.org · October 1, 2026